Garcia-Manero, G., Platzbecker, U., Fenaux, P., Roboz, G., Fong, C. Y., Hus, M., Delage, R., Brunner, A., Lee, J., Turgut, M., Mazure, D., Feng, Y., Miyazaki, Y., Kořístek, Z., Salazar, S., Paolini, S., Diez-Campelo, M., Lavie, D., Culligan, D., Ku, G., Xiao, Z., Fang, F., Headley, M., Potluri, J., Zeidan, A., Garcia, J. (2025). Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS). Blood. https://doi.org/10.1182/blood-2025-235